Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids.
2026 · 2nd Quarter (Apr 1 - June 30)
JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES
Filed by MARSHALL & POPP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 9, 2026
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- MARSHALL & POPP, LLC
- Filing UUID
- 38a7b974-11cc-4e77-9b3d-18a93eae42be
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to tariff and trade policy.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.